Larvol Delta - SynuSight-Biotech-ABLi-Therapeutics-and-XingImaging-Announce-Strategic-Collaboration-to-Implement-AlphaSynuclein-PET-Imaging-into-Clinical-Trials-Evaluating-Risvodetinib-as-a-Diseasemodifying-Therapy-for-Parkinsons-Disease

risvodetinib (ABLi-148009) - ABLi Therapeutics

https://www.globenewswire.com/news-release/2026/01/05/3212752/0/en/SynuSight-Biotech-ABLi-Therapeutics-and-XingImaging-Announce-Strategic-Collaboration-to-Implement-Alpha-Synuclein-PET-Imaging-into-Clinical-Trials-Evaluating-Risvodetinib-as-a-Dise.html

Jan 8, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next